Out-license therapeutics and IP to the right global partner.

Out-licensing is granting another company the rights to develop or sell your drug candidate, platform or IP, in return for upfront, milestone and royalty payments. An out-licensing advisor assesses what is licensable, prepares the non-confidential summary and data room, approaches qualified buyers under NDA, compares offers and negotiates through the signed agreement. Vision Lifesciences is one of the leading cross-border licensing advisors.

The best timing is usually before a financing or development inflection forces urgency. We often begin when there is enough data to support differentiated value, but before the seller is locked into one funding path.

Clinical-stage programs, platforms, preclinical assets with differentiated data and non-core commercial products. Stage shapes the structure: earlier clinical and platform programs often suit an option-to-license, while later assets usually go through a regional or global license.

Oncology, immunology, metabolic disease, CNS and rare disease. On the modality side we cover small molecules, biologics, ADCs and bispecifics, cell and gene therapies, and peptide and RNA assets; devices and diagnostics more selectively.

For most deals, little changes. China’s Announcement No. 48 of October 2026 proposes export controls on five biotech technologies, mainly cell and gene therapy and siRNA platforms, and requires registration before a listed technology is exported. Most single-product licenses of antibodies, ADCs or small molecules do not involve the listed technologies, though they still need the usual technology-export contract registration. Platform transfers and changes of control are where the rules bite. See our guide to the COINS Act and China’s new rules.

It depends on where your own capabilities and capital end. A regional license, such as ex-China rights, lets you keep the markets you can develop yourself; a global license moves development cost and risk to one partner. We model both before any buyer is approached.

Usually a small share. Across biopharma licensing deals announced from January to September 2026, upfront cash was about 6% of headline value (J.P. Morgan); China-based drugmakers’ overseas licensing deals carried about $8 billion of upfronts in the first three quarters of 2026, against $139.4 billion in headline value by early October (PharmCube). The rest depends on development, regulatory and sales milestones and royalties, so milestone design matters as much as the upfront.

Yes. In a NewCo deal, the asset is licensed into a new company funded by outside investors, and the seller typically keeps equity alongside upfront cash, milestones or royalties. It suits programs that need dedicated capital and a focused team; our NewCo formation practice designs these structures.

Engagements are generally structured with a retainer and success component aligned to signing. The exact structure depends on asset stage, geography, mandate scope, and process complexity.